References
- Ahmad S, Gromiha M, Fawareh H, Sarai A (2004). ASAView: database and tool for solvent accessibility representation in proteins. BMC Bioinformatics, 5, 824-27.
- Bandaru S, Tiwari G, Akka J, et al (2015). Identification of high affinity bioactive salbutamol conformer directed against mutated (Thr164Ile) Beta 2 adrenergic receptor. Cur Top Med Chem, 15, 50-56. https://doi.org/10.2174/1568026615666150112113040
- Basse MJ, Betzi S, Bourgeas R, et al (2013). 2P2Idb: a structural database dedicated to orthosteric modulation of proteinprotein interactions. Nucleic Acids Res, 41, 824-27. https://doi.org/10.1093/nar/gks1002
- Blume-Jensen P, Hunter T (2001). Oncogenic kinase signalling. Nature, 411, 355-65. https://doi.org/10.1038/35077225
- Cheng F, Li W, Zhou Y, et al (2012). admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J chem inf and model, 52, 3099-105. https://doi.org/10.1021/ci300367a
- Dahabreh IJ, Terasawa T, Castaldi PJ, et al (2011). Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Annal Inter Med, 154, 37-49. https://doi.org/10.7326/0003-4819-154-1-201101040-00006
- Ferguson KM, Berger MB, Mendrola JM, et al (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Molecular Cell, 11, 507-17. https://doi.org/10.1016/S1097-2765(03)00047-9
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Caner, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jemal A, Siegel R, Xu J, (2010). Cancer Statistics. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
- Jorgensen WL, Maxwell DS, Tirado-Rives J (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc, 118, 11225-36. https://doi.org/10.1021/ja9621760
- Lacouture M, Basti S, Patel J, et al (2006). The SERIES Clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol, 4, 236-8.
- Lacouture ME, Maitland ML, Segaert S, et al (2010). A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer, 18, 509-22. https://doi.org/10.1007/s00520-009-0744-x
- LigPrep, V. (2010). 2.4, Schrodinger. LLC, New York.
- Lynch TJ, Kim ES, Eaby B, et al (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist, 12, 610-21. https://doi.org/10.1634/theoncologist.12-5-610
- Marino P, Pampallona S, Preatoni A, et al (1994). Chemotherapy vs supportive care in advanced non-smallcell lung cancer. Results of a meta-analysis of the literature. Chest, 106, 861-5. https://doi.org/10.1378/chest.106.3.861
- Nelder JA, Mead R (1965). A simplex method for function minimization. The comput J, 7, 308-13. https://doi.org/10.1093/comjnl/7.4.308
- Pirker R, Pereira JR, Szczesna A, et al (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet, 373, 1525-31. https://doi.org/10.1016/S0140-6736(09)60569-9
- Reichmann D, Phillip Y, Carmi A, Schreiber G (2008). On the contribution of water-mediated interactions to proteincomplex stability. Biochemistry, 47, 1051-60. https://doi.org/10.1021/bi7019639
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Schneidman-Duhovny D, Inbar Y, Nussinov R, et al (2005). PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res, 33, 363-7 https://doi.org/10.1093/nar/gki481
- Stinchcombe TE, Bradford DS, Hensing TA, et al (2010). A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced non small cell lung cancer. Cancer Invest, 28, 208-15.
- Takiar R, Nadayil D, Nandakumar A (2010). Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev, 11, 1045-49.
- Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37. https://doi.org/10.1016/S0140-6736(05)67625-8
- Ullrich A, Schlessinger J (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-212. https://doi.org/10.1016/0092-8674(90)90801-K
- Usuda K, Sagawa M, Motono N, et al (2013). Relationships between EGFR mutation status of lung cancer and preoperative factors-are they predictive? Asian Pac J Cancer Prev, 15, 657-62.
- Wang YS, Wang YH, Xia H, et al (2012). MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/ AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev, 13, 255-60. https://doi.org/10.7314/APJCP.2012.13.1.255
- Yang JM, Chen CC (2004). Gemdock: A generic evolutionary method for molecular docking. Proteins, 55, 288-304 https://doi.org/10.1002/prot.20035
- Yang ZY, Liu L, Mao C, et al (2014). Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy naive advanced non small cell lung cancer. Cochrane Database Syst Rev, 11, 9948.